Vivimed Labs is currently trading at Rs. 103.85, up by 11.50 points or 12.45% from its previous closing of Rs. 92.35 on the BSE.
The scrip opened at Rs. 104.35 and has touched a high and low of Rs. 107.40 and Rs. 102.25 respectively. So far 2,61,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 121.15 on 04-Oct-2016 and a 52 week low of Rs. 68.00 on 09-Aug-2016.
Last one week high and low of the scrip stood at Rs. 107.40 and Rs. 84.00 respectively. The current market cap of the company is Rs. 841.38 crore.
The promoters holding in the company stood at 37.23%, while Institutions and Non-Institutions held 2.87% and 59.90% respectively.
Vivimed Labs’ FDF manufacturing facility located in Alathur, near Chennai had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The facility has successfully completed USFDA inspection. The audit was conducted during the last week of November and concluded on November 28, 2016.
Furthermore, Vivimed obtained ANDA approval for Metronidazole and same is commercialized. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialized by Q4 FY2017. The company is on track of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expects one more filing to be completed by Q4 FY2017. These products provide vertical integration with the in-house APIs.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
